Merck Sharp + Dohme Corp.

Merck Sharp + Dohme B.v.

Sachin Mittal

Jason W Skudlarek

Izzat Tiedje Raheem

Sutthilug Sotthivirat

Himanshu Bhattacharjee

Sachin Lohani

Irina Kazakevich

Luke R Schenck

Sergei Pechenov

Peter Bakker

Nazia Khawaja

David J Goldfarb

Hossain Jahansouz

Amitava Mitra

Sutthilug Sottivirat

Suzanne M D'Addio

Donna Carroll

Daniel Hong Yin

The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pro drugs of PDE10 compounds

Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.

Pharmaceutical compositions of a peptide

The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).

Formulation for parenteral administration

A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature T(s) of at least about 90&#xb0; C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature T(c) of at least about 55&#xb0; C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.

Lyophilized anti-fungal compositions

Growing community of inventors

Bridgewater, NJ, United States of America

Sachin Mittal